Tracking vector insertion sites to explore the biology of transduced cells in vivo [electronic resource] / Christof Von Kalle.

By: Von Kalle, Christof [spk]Material type: FilmFilmSeries: Henry Stewart talksBiomedical & life sciences collection. Gene transfer and gene therapy: Publisher: London : Henry Stewart Talks, 2014Description: 1 online resource (1 streaming video file (35 min.) : color, sound)Subject(s): Gene therapy | Genetic transformation | Genetic vectors | Lentiviruses | Medical genetics | Genetic Therapy -- methods | Genetic Vectors -- genetics | Hematopoietic System | Lentivirus -- genetics | Severe Combined Immunodeficiency | Virus Integration -- genetics | Wiskott-Aldrich Syndrome -- therapy | X-Linked Combined Immunodeficiency DiseasesOnline resources: Click here to access online | Series
Contents:
Contents: Clonal marking by integrating vectors -- Integration site analysis by LAM-PCR -- Analysis of gene therapy clinical trials for X-SCID, X-CGD, ADA-SCID & Cancer -- Avoiding oncogenesis in gene therapy -- Gene therapy for Wiskott-Aldrich Syndrome (WAS) -- Characterization & understanding of pathogenesis -- Integrations in known proto-oncogenes -- Possible triggers of AML development -- Safer vector systems & new technologies -- Lentiviral SIN-vectors -- Influence of vector type on clinical outcome -- LV integration site analysis: X-ALD trial -- Repopulation of hematopoietic system -- Targeted genome modification: nucleases -- Specificity of DNA modification by ZFN -- The TALEN nuclease and how it performs.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
No physical items for this record

Animated audio-visual presentation with synchronized narration.

Title from title frames.

Contents: Clonal marking by integrating vectors -- Integration site analysis by LAM-PCR -- Analysis of gene therapy clinical trials for X-SCID, X-CGD, ADA-SCID & Cancer -- Avoiding oncogenesis in gene therapy -- Gene therapy for Wiskott-Aldrich Syndrome (WAS) -- Characterization & understanding of pathogenesis -- Integrations in known proto-oncogenes -- Possible triggers of AML development -- Safer vector systems & new technologies -- Lentiviral SIN-vectors -- Influence of vector type on clinical outcome -- LV integration site analysis: X-ALD trial -- Repopulation of hematopoietic system -- Targeted genome modification: nucleases -- Specificity of DNA modification by ZFN -- The TALEN nuclease and how it performs.

Access restricted to subscribers.

Mode of access: World Wide Web.

Technical University of Mombasa
Tom Mboya Street, Tudor 90420-80100 , Mombasa Kenya
Tel: (254)41-2492222/3 Fax: 2490571